BCM
RNAC icon

Bridgeway Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Bridgeway Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Buy
32,500
+7,500
+30% +$55.6K 0.01% 950
2026
Q1 		$154K Hold
25,000
– – ﹤0.01% 1073
2025
Q4 		$180K Hold
25,000
– – ﹤0.01% 1039
2025
Q3 		$256K Buy
+25,000
New +$281K 0.01% 966
2024
Q4 		– Sell
-10,193
Closed -$164K – 1282
2024
Q3 		$164K Hold
10,193
– – ﹤0.01% 1102
2024
Q2 		$275K Hold
10,193
– – 0.01% 982
2024
Q1 		$199K Sell
10,193
-5,000
-33% -$106K ﹤0.01% 1111
2023
Q4 		$314K Hold
15,193
– – 0.01% 1057
2023
Q3 		$483K Hold
15,193
– – 0.01% 877
2023
Q2 		$510K Buy
15,193
+693
+5% +$24.8K 0.01% 891
2023
Q1 		$605K Buy
+14,500
New +$682K 0.02% 839
2022
Q4 		– Sell
-640
Closed -$31K – 1448
2022
Q3 		$31K Buy
+640
New +$35.2K ﹤0.01% 1372
2020
Q2 		– Sell
-6,603
Closed -$477K – 1385
2020
Q1 		$477K Sell
6,603
-1,167
-15% -$113K 0.01% 780
2019
Q4 		$555K Buy
7,770
+5,500
+242% +$265K 0.01% 935
2019
Q3 		$119K Hold
2,270
– – ﹤0.01% 1233
2019
Q2 		$122K Buy
+2,270
New +$155K ﹤0.01% 1232
2018
Q4 		– Sell
-1,667
Closed -$778K – 1438
2018
Q3 		$778K Sell
1,667
-833
-33% -$335K 0.01% 1001
2018
Q2 		$994K Hold
2,500
– – 0.01% 878
2018
Q1 		$764K Buy
2,500
+1,667
+200% +$475K 0.01% 936
2017
Q4 		$245K Hold
833
– – ﹤0.01% 1247
2017
Q3 		$456K Hold
833
– – 0.01% 1118
2017
Q2 		$497K Buy
+833
New +$368K 0.01% 1093

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bridgeway Capital Management's RNAC Position: Q2 2026 in Review

Bridgeway Capital Management increased its Cartesian Therapeutics (RNAC) stake by 30% in Q2 2026, buying an estimated $55.6K and bringing the position to 32,500 shares worth $339K. The position accounts for 0.01% of the portfolio, ranked #950.

Bridgeway Capital Management first reported a position in RNAC in Q2 2017 and has held it in 22 quarters since. The position peaked at $994K in Q2 2018. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Bridgeway Capital Management held 32,500 shares of Cartesian Therapeutics worth $339K as of Q2 2026.
  • Bridgeway Capital Management bought 7,500 Cartesian Therapeutics shares in Q2 2026, an estimated $55.6K.
  • Cartesian Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #950 holding.
  • Bridgeway Capital Management first reported a position in Cartesian Therapeutics in Q2 2017 and has held it in 22 quarters since.
  • Bridgeway Capital Management's Cartesian Therapeutics position peaked at $994K in Q2 2018.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.